What is the difference between totect and zinecard

In the registration studies for dexrazoxane, there was initially a higher rate of superficial phlebitis when dexrazoxane was first given at the doses used for extravasation. This adverse event was diminished in subsequent studies after buffer changes to the solvent were made. Dexrazoxane hydrochloride is the only product with the indication for treatment of anthracycline extravasations that also has a U.

Based on this patent, substitution of other forms of dexrazoxane for anthracycline extravasation treatment constitutes patent infringement. The medical and legal implications of this dilemma are unclear at this time. Prevention is the primary goal for protecting patients from extravasation injury due to anthracyclines. The use of specific guidelines for infusion and administration through a CVAD appear to reduce the incidence of vesicant extravasations Table 2.

However, accidental extravasations still occur. The use of antidotes for anthracycline extravasations has been controversial. Clinical trial data suggest that dexrazoxane hydrochloride is an effective treatment of anthracycline extravasations, and provides a therapeutic option for a rare, but potentially damaging adverse effect of chemotherapy.

Whether national extravasation guidelines will accept this agent as a standard remains to be seen. However, there appears to be a number of important unanswered questions. Issue: January 1, By Janet Espirito, PharmD. Read next. January 01, Receive an email when new articles are posted on. Please provide your email address to receive an email when new articles are posted on. You've successfully added to your alerts.

You will receive an email when new content is published. Click Here to Manage Email Alerts. We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice slackinc. Back to Healio. Related Content. Please refresh your browser and try again.

Diagnosis and Staging. Questions to Ask about Your Diagnosis. Types of Cancer Treatment. Side Effects of Cancer Treatment. Clinical Trials Information. A to Z List of Cancer Drugs.

Questions to Ask about Your Treatment. Feelings and Cancer. Adjusting to Cancer. Day-to-Day Life. Support for Caregivers. Questions to Ask About Cancer. Choices for Care. Talking about Your Advanced Cancer. Planning for Advanced Cancer. Advanced Cancer and Caregivers. Questions to Ask about Advanced Cancer. Managing Cancer Care. Finding Health Care Services. Advance Directives. Using Trusted Resources. Coronavirus Information for Patients.

Clinical Trials during Coronavirus. Adolescents and Young Adults with Cancer. Emotional Support for Young People with Cancer. Cancers by Body Location. Late Effects of Childhood Cancer Treatment. Pediatric Supportive Care. Rare Cancers of Childhood Treatment. Childhood Cancer Genomics. Study Findings. Metastatic Cancer Research. Intramural Research. Extramural Research. Cancer Research Workforce. Partners in Cancer Research.

What Are Cancer Research Studies. Research Studies. Get Involved. Cancer Biology Research. Cancer Genomics Research. Research on Causes of Cancer. Cancer Prevention Research. Cancer Treatment Research. Cancer Health Disparities. Childhood Cancers Research. Global Cancer Research. Cancer Research Infrastructure. Clinical Trials. Frederick National Laboratory for Cancer Research. Bioinformatics, Big Data, and Cancer. Annual Report to the Nation. Research Advances by Cancer Type.

Stories of Discovery. Milestones in Cancer Research and Discovery. Dexrazoxane injection is in classes of medications called cardioprotectants and chemoprotectants. It works by stopping the chemotherapy medications from damaging the heart and the tissues. Dexrazoxane injection comes as a powder to be mixed with liquid and injected into a vein by a doctor or nurse in a hospital. When dexrazoxane injection is used to prevent heart damage caused by doxorubicin, it is given over 15 minutes just before each dose of doxorubicin.

When dexrazoxane injection is used to prevent tissue damage after an anthracycline medication has leaked out of a vein, it is given over 1 to 2 hours once a day for 3 days. The first dose is given as soon as possible within the first 6 hours after the leak occurs, and the second and third doses are given about 24 and 48 hours after the first dose.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information. Some people who took a medication that is very similar to dexrazoxane injection developed new forms of cancer. There is not enough information to tell if receiving dexrazoxane injection increases the risk that you will develop a new type of cancer.

Talk to your doctor about the risks of receiving this medication. Dexrazoxane injection may cause other side effects. Call your doctor if you have any unusual problems while receiving this medication. In case of overdose, call the poison control helpline at If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at Keep all appointments with your doctor and the laboratory.

Your doctor will order certain lab tests to check your body's response to dexrazoxane injection. It is important for you to keep a written list of all of the prescription and nonprescription over-the-counter medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements.